Affiliation:
1. Tianjin Key Laboratory of Biomedical Materials Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy Institute of Biomedical Engineering Chinese Academy of Medical Sciences and Peking Union Medical College Tianjin 300192 P. R. China
2. Department of Pharmacy Qujing Medical College Qujing Yunnan 655000 P. R. China
3. Xiangya School of Pharmaceutical Sciences Central South University Changsha Hunan 410013 P. R. China
Abstract
AbstractChimeric antigen receptor (CAR) cell therapy is a great success and breakthrough in immunotherapy. However, there are still lots of barriers to its wide use in clinical, including long time consumption, high cost, and failure against solid tumors. For these challenges, researches are deplored to explore CAR cells to more appliable products in clinical. This minireview focuses on the advanced non‐viral materials for CAR‐T transfection ex vivo with better performance, delivery systems combined with other therapy for enhancement of CAR‐T therapy in solid tumors. In addition, the targeted delivery platform for CAR cells in vivo generation as a breakthrough technology as its low cost and convenience. In the end, the prospective direction and future of CAR cell therapy are discussed.
Funder
National Natural Science Foundation of China
Fundamental Research Funds for the Central Universities
Subject
General Materials Science,General Chemistry
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献